The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Impact of Vascular Endothelial Growth Factor-A Expression, Thrombospondin-2 Expression, and Microvessel Density on the Treatment Effect of Bevacizumab in Metastatic Colorectal Cancer
Open accessAbstract
Purpose: Bevacizumab is a monoclonal antibody to vascular endothelial growth factor-A (VEGF). In the pivotal trial in metastatic colorectal cancer (mCRC), addition of bevacizumab to first-line irinotecan, fluorouracil, and leucovorin (IFL) significantly prolonged median survival. The aim of these retrospective subset analyses was to evaluate VEGF, thrombospondin-2 (THBS-2), and microvessel density (MVD) as prognostic factors and/or predictors of benefit from bevacizumab. Patients and Methods: In the pivotal trial, 813 patients with untreated mCRC were randomly assigned to receive IFL plus bevacizumab or placebo. Of 312 tissue samples collected (285 primaries, 27 metastases), outcome data were available for 278 (153 bevacizumab, 125 placebo). Epithelial and stromal VEGF expression were assessed by in situ hybridization (ISH) and immunohistochemistry on tissue microarrays and whole sections. Stromal THBS-2 expression was examined by ISH on tissue microarrays. MVD was quantified by Chalkley count. Overall survival was associated with these variables in retrospective subset analyses. Results: In all subgroups, estimated hazard ratios (HRs) for risk of death were < 1 for bevacizumab-treated patients regardless of the level of VEGF or THBS-2 expression or MVD. Patients with a high THBS-2 score showed a nonsignificant improvement in survival following bevacizumab treatment (HR = 0.11; 95% CI, 0.02 to 0.51) compared to patients with a low score (HR = 0.65; 95% CI, 0.41 to 1.02); interaction analysis P = .22. VEGF or THBS-2 expression and MVD were not significant prognostic factors. Conclusion: These exploratory analyses suggest that in patients with mCRC addition of bevacizumab to IFL improves survival regardless of the level of VEGF or THBS-2 expression, or MVD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Self-citationThe Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
Tissue microarrays for high-throughput molecular profiling of tumor specimens
Kononen, J., Bubendorf, L., Kallionimeni, A., Bärlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,099
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Self-citationGlobal cancer statistics in the year 2000
Parkin, D. M. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(01)00486-7 · Cited by 2,445
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966
Presta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., KRUMMEN, L. A., Winkler, M., & Ferrara, N. (1997) · PubMed · Cited by 1,608
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,370
Cited by
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
Normalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605
Stem Cell–like Glioma Cells Promote Tumor Angiogenesis through Vascular Endothelial Growth Factor
Bao, S., Wu, Q., Sathornsumetee, S., Hao, Y., Li, Z., Hjelmeland, A. B., Shi, Q., McLendon, R. E., Bigner, D. D., & Rich, J. N. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1010 · Cited by 1,345
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
Jain, R. K., Duda, D. G., Clark, J. W., & Loeffler, J. S. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0403 · Cited by 1,039
Schneider, B. P., Wang, M., Radovich, M., Sledge, G. W., Badve, S., Thor, A., Flockhart, D. A., Hancock, B., Davidson, N., Gralow, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1612 · Cited by 604
Vascular endothelial growth factor (VEGF) signaling in tumor progression
Roskoski, R. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.01.006 · Cited by 599
Biomarkers of response and resistance to antiangiogenic therapy
Jain, R. K., Duda, D. G., Willett, C. G., Sahani, D. V., Zhu, A. X., Loeffler, J. S., Batchelor, T. T., & Sorensen, A. G. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.63 · Cited by 572
Health benefits of resveratrol: Evidence from clinical studies
Singh, A. P., Singh, R., Verma, S. S., Rai, V., Kaschula, C. H., Maiti, P., & Gupta, S. C. (2019) · Medicinal Research Reviews · doi:10.1002/med.21565 · Cited by 523
Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies
Shih, T., & Lindley, C. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.11.015 · Cited by 521
Batchelor, T. T., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Plotkin, S. R., Gerstner, E., Eichler, A. F., Drappatz, J., Hochberg, F. H., Benner, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3988 · Cited by 520
Willett, C. G., Duda, D. G., di Tomaso, E., Boucher, Y., Ancukiewicz, M., Sahani, D. V., Lahdenranta, J., Chung, D. C., Fischman, A. J., Lauwers, G. Y., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1771 · Cited by 508
Siegel, A. B., Cohen, E. I., Ocean, A., Lehrer, D., Goldenberg, A., Knox, J. J., Chen, H., Clark-Garvey, S., Weinberg, A., Mandeli, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9947 · Cited by 506
The Role of CXCR7/RDC1 as a Chemokine Receptor for CXCL12/SDF-1 in Prostate Cancer
Wang, J., Shiozawa, Y., Wang, J., Wang, Y., Jung, Y., Pienta, K. J., Mehra, R., Loberg, R., & Taichman, R. S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707465200 · Cited by 457
RetractedTargeted Therapy for Metastatic Renal Cell Carcinoma
Motzer, R. J., & Bukowski, R. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.5415 · Cited by 454
Des Guetz, G., Uzzan, B., Nicolas, P., Cucherat, M., Morere, J.-F., Benamouzig, R., Breau, J.-L., & Perret, G.-Y. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603176 · Cited by 406
Metastasis: a therapeutic target for cancer
Steeg, P. S., & Theodorescu, D. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1066 · Cited by 332
Scartozzi, M., Galizia, E., Chiorrini, S., Giampieri, R., Berardi, R., Pierantoni, C., & Cascinu, S. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn637 · Cited by 327
Bukowski, R. M., Kabbinavar, F. F., Figlin, R. A., Flaherty, K., Srinivas, S., Vaishampayan, U., Drabkin, H. A., Dutcher, J., Ryba, S., Xia, Q., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5154 · Cited by 315
Self-citationBiomarkers to predict the clinical efficacy of bevacizumab in cancer
Jubb, A. M., & Harris, A. L. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70232-1 · Cited by 295
Self-citationSandmann, T., Bourgon, R., Garcia, J., Li, C., Cloughesy, T., Chinot, O. L., Wick, W., Nishikawa, R., Mason, W., Henriksson, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.5005 · Cited by 293
Dowlati, A., Gray, R., Sandler, A. B., Schiller, J. H., & Johnson, D. H. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1154 · Cited by 263
Sathornsumetee, S., Cao, Y., Marcello, J. E., Herndon, J. E., McLendon, R. E., Desjardins, A., Friedman, H. S., Dewhirst, M. W., Vredenburgh, J. J., & Rich, J. N. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.3652 · Cited by 261
Loges, S., Schmidt, T., & Carmeliet, P. (2010) · Genes & Cancer · doi:10.1177/1947601909356574 · Cited by 257
Anti-VEGF therapies in the clinic
Meadows, K. L., & Hurwitz, H. I. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006577 · Cited by 237
“factors and oncogenes known to regulate important angiogenesis factors (Jubb et al. 2006).”
InfluentialSelf-citationHegde, P. S., Jubb, A. M., Chen, D., Li, N. F., Meng, Y. G., Bernaards, C., Elliott, R., Scherer, S. J., & Chen, D. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2535 · Cited by 193
“development, and analysis were carried out as described previously (24, 32).”
BackgroundMethodSelf-citationGalsky, M. D., Eisenberger, M., Moore-Cooper, S., Kelly, W. K., Slovin, S. F., DeLaCruz, A., Lee, Y., Webb, I. J., & Scher, H. I. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0532 · Cited by 145
Metadata
- Authors
- Jubb, A. M., Hurwitz, H. I., Bai, W., Holmgren, E. B., Tobin, P., Guerrero, A. S., Kabbinavar, F., Holden, S. N., Novotny, W. F., Frantz, G. D., Hillan, K. J., & Koeppen, H.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-01-10
- Volume
- 24
- Issue
- 2
- Pages
- 217-227
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2157019123
- Cited by
- 387
- References
- 55
- FWCI
- 14.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.